Cerus Corporation to Present at the 2021 Cantor Global Virtual Healthcare Conference

Rhea-AI Summary

Cerus Corporation (Nasdaq: CERS) announces participation in the 2021 Cantor Global Virtual Healthcare Conference on September 29, 2021, at 11:20 a.m. ET. CEO William 'Obi' Greenman and CFO Kevin D. Green will represent the company. A live webcast will be accessible on Cerus’ Investor Relations page, with a replay available for two weeks post-event. Cerus is committed to protecting the global blood supply, offering the INTERCEPT Blood System, which has CE mark and FDA approval for pathogen reduction in platelets and plasma. For further details, visit Cerus Investor Relations.

CONCORD, Calif.--(BUSINESS WIRE)-- Cerus Corporation (Nasdaq: CERS) today announced that William ‘Obi’ Greenman, Cerus’ president and chief executive officer, and Kevin D. Green, Cerus’ chief financial officer, are scheduled to participate in the 2021 Cantor Global Virtual Healthcare Conference on Wednesday, September 29, 2021 at 11:20 a.m. ET.

A live webcast of the presentation will be available on Cerus’ Investor Relations page at http://www.cerus.com/ir. A replay of the webcast will be available for approximately two weeks following the completion of the event.

ABOUT CERUS

Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the US. Also in the US, the INTERCEPT Blood System for Cryoprecipitation is approved for the production of INTERCEPT Fibrinogen Complex, a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. For more information about Cerus, visit www.cerus.com and follow us on LinkedIn.

INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210915005111/en/

Matt Notarianni – Senior Director, Investor Relations

Cerus Corporation

925-288-6137

Source: Cerus Corporation

FAQ

When is Cerus Corporation participating in the Cantor Global Virtual Healthcare Conference?

Cerus Corporation will participate in the 2021 Cantor Global Virtual Healthcare Conference on September 29, 2021, at 11:20 a.m. ET.

Who from Cerus Corporation will speak at the healthcare conference?

CEO William 'Obi' Greenman and CFO Kevin D. Green will represent Cerus Corporation at the conference.

How can I watch the Cerus Corporation conference presentation?

The presentation will be available via a live webcast on Cerus’ Investor Relations page at http://www.cerus.com/ir.

Will there be a replay of the Cerus conference presentation?

Yes, a replay of the webcast will be available for approximately two weeks after the event.

What is the main focus of Cerus Corporation?

Cerus Corporation is dedicated to safeguarding the world’s blood supply, developing pathogen-protected blood components.